WILDBRAIN SHAREHOLDERS APPROVE ALL MATTERS AT ANNUAL MEETING
The detailed results of the votes received for each director nominee were as follows:
Directors | % of Votes For | % of Votes Against |
99.21 % | 0.79 % | |
Erin Elofson | 99.22 % | 0.78 % |
Thomas McGrath | 94.68 % | 5.32 % |
Rita Middleton | 94.70 % | 5.30 % |
Josh Scherba | 99.22 % | 0.78 % |
Jonathan Whitcher | 94.61 % | 5.39 % |
94.70 % | 5.30 % |
As the Company continues to focus on key franchises to drive the greatest opportunity for growth and shareholder value, the Board of Directors (the "Board") has determined to reduce the number of directors from 10 to seven. As such, former directors
For more information, please contact:
Investors:
[email protected]
+1 212-405-6089
Media:
[email protected]
+1 416-977-7230
About WildBrain
At WildBrain we inspire imaginations through the wonder of storytelling. As a leader in 360° franchise management, we are experts in content creation, audience engagement and global licensing, cultivating and growing love for our own and partner brands around the world. With approximately 14,000 half-hours of kids' and family content in our library—one of the world's most extensive—we are home to such treasured franchises as Peanuts, Teletubbies, Strawberry Shortcake,
Our studios produce such award-winning series as The Snoopy Show; Snoopy in Space; Camp Snoopy; Strawberry Shortcake: Berry in the Big City; Sonic Prime; Chip and Potato; Teletubbies Let's Go! and many more. Enjoyed in more than 150 countries on over 500 platforms, our content is everywhere kids and families view entertainment, including YouTube, where our network has garnered approximately 1.5 trillion minutes of watch time. Our television group owns and operates some of
WildBrain is headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/wildbrain-shareholders-approve-all-matters-at-annual-meeting-302336624.html
SOURCE WildBrain Ltd.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ALZpath Demonstrates Global Clinical Impact at AAIC 2026, with Proprietary pTau217 Antibody Anchoring 86 Presentations Demonstrating Clinical and Diagnostic Value Across the Translational Pipeline
- Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference® (AAIC®) 2026
- Webuy Launches AI Agent-Assisted Smart Travel Card to Enhance Connected Travel Experience
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share